Cargando…

Double Recombinant Vaccinia Virus: A Candidate Drug against Human Glioblastoma

Glioblastoma is one of the most aggressive brain tumors. Given the poor prognosis of this disease, novel methods for glioblastoma treatment are needed. Virotherapy is one of the most actively developed approaches for cancer therapy today. VV-GMCSF-Lact is a recombinant vaccinia virus with deletions...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasileva, Natalia, Ageenko, Alisa, Dmitrieva, Maria, Nushtaeva, Anna, Mishinov, Sergey, Kochneva, Galina, Richter, Vladimir, Kuligina, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538059/
https://www.ncbi.nlm.nih.gov/pubmed/34685455
http://dx.doi.org/10.3390/life11101084
_version_ 1784588417127940096
author Vasileva, Natalia
Ageenko, Alisa
Dmitrieva, Maria
Nushtaeva, Anna
Mishinov, Sergey
Kochneva, Galina
Richter, Vladimir
Kuligina, Elena
author_facet Vasileva, Natalia
Ageenko, Alisa
Dmitrieva, Maria
Nushtaeva, Anna
Mishinov, Sergey
Kochneva, Galina
Richter, Vladimir
Kuligina, Elena
author_sort Vasileva, Natalia
collection PubMed
description Glioblastoma is one of the most aggressive brain tumors. Given the poor prognosis of this disease, novel methods for glioblastoma treatment are needed. Virotherapy is one of the most actively developed approaches for cancer therapy today. VV-GMCSF-Lact is a recombinant vaccinia virus with deletions of the viral thymidine kinase and growth factor genes and insertions of the granulocyte–macrophage colony-stimulating factor and oncotoxic protein lactaptin genes. The virus has high cytotoxic activity against human cancer cells of various histogenesis and antitumor efficacy against breast cancer. In this work, we show VV-GMCSF-Lact to be a promising therapeutic agent for glioblastoma treatment. VV-GMCSF-Lact effectively decreases the viability of glioblastoma cells of both immortalized and patient-derived cultures in vitro, crosses the blood–brain barrier, selectively replicates into orthotopically transplanted human glioblastoma when intravenously injected, and inhibits glioblastoma xenograft and metastasis growth when injected intratumorally.
format Online
Article
Text
id pubmed-8538059
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85380592021-10-24 Double Recombinant Vaccinia Virus: A Candidate Drug against Human Glioblastoma Vasileva, Natalia Ageenko, Alisa Dmitrieva, Maria Nushtaeva, Anna Mishinov, Sergey Kochneva, Galina Richter, Vladimir Kuligina, Elena Life (Basel) Article Glioblastoma is one of the most aggressive brain tumors. Given the poor prognosis of this disease, novel methods for glioblastoma treatment are needed. Virotherapy is one of the most actively developed approaches for cancer therapy today. VV-GMCSF-Lact is a recombinant vaccinia virus with deletions of the viral thymidine kinase and growth factor genes and insertions of the granulocyte–macrophage colony-stimulating factor and oncotoxic protein lactaptin genes. The virus has high cytotoxic activity against human cancer cells of various histogenesis and antitumor efficacy against breast cancer. In this work, we show VV-GMCSF-Lact to be a promising therapeutic agent for glioblastoma treatment. VV-GMCSF-Lact effectively decreases the viability of glioblastoma cells of both immortalized and patient-derived cultures in vitro, crosses the blood–brain barrier, selectively replicates into orthotopically transplanted human glioblastoma when intravenously injected, and inhibits glioblastoma xenograft and metastasis growth when injected intratumorally. MDPI 2021-10-14 /pmc/articles/PMC8538059/ /pubmed/34685455 http://dx.doi.org/10.3390/life11101084 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Vasileva, Natalia
Ageenko, Alisa
Dmitrieva, Maria
Nushtaeva, Anna
Mishinov, Sergey
Kochneva, Galina
Richter, Vladimir
Kuligina, Elena
Double Recombinant Vaccinia Virus: A Candidate Drug against Human Glioblastoma
title Double Recombinant Vaccinia Virus: A Candidate Drug against Human Glioblastoma
title_full Double Recombinant Vaccinia Virus: A Candidate Drug against Human Glioblastoma
title_fullStr Double Recombinant Vaccinia Virus: A Candidate Drug against Human Glioblastoma
title_full_unstemmed Double Recombinant Vaccinia Virus: A Candidate Drug against Human Glioblastoma
title_short Double Recombinant Vaccinia Virus: A Candidate Drug against Human Glioblastoma
title_sort double recombinant vaccinia virus: a candidate drug against human glioblastoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538059/
https://www.ncbi.nlm.nih.gov/pubmed/34685455
http://dx.doi.org/10.3390/life11101084
work_keys_str_mv AT vasilevanatalia doublerecombinantvacciniavirusacandidatedrugagainsthumanglioblastoma
AT ageenkoalisa doublerecombinantvacciniavirusacandidatedrugagainsthumanglioblastoma
AT dmitrievamaria doublerecombinantvacciniavirusacandidatedrugagainsthumanglioblastoma
AT nushtaevaanna doublerecombinantvacciniavirusacandidatedrugagainsthumanglioblastoma
AT mishinovsergey doublerecombinantvacciniavirusacandidatedrugagainsthumanglioblastoma
AT kochnevagalina doublerecombinantvacciniavirusacandidatedrugagainsthumanglioblastoma
AT richtervladimir doublerecombinantvacciniavirusacandidatedrugagainsthumanglioblastoma
AT kuliginaelena doublerecombinantvacciniavirusacandidatedrugagainsthumanglioblastoma